NOT.DE - Novartis AG

XETRA - XETRA Delayed price. Currency in EUR
63.16
-0.46 (-0.72%)
As of 5:35PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close63.62
Open63.50
Bid0.00 x 76600
Ask0.00 x 36400
Day's range62.96 - 63.94
52-week range62.80 - 77.66
Volume17,147
Avg. volume16,555
Market cap146.734B
Beta0.67
PE ratio (TTM)19.43
EPS (TTM)3.25
Earnings dateN/A
Forward dividend & yield2.39 (3.61%)
Ex-dividend dateN/A
1y target estN/A
  • Novartis' digital drive continues with eye-disease app
    Reuters29 minutes ago

    Novartis' digital drive continues with eye-disease app

    Novartis's foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies. It is using Apple's ResearchKit for its "FocalView" application to help researchers track ophthalmic disease progression by collecting data directly from patients without requiring them to travel to a doctor. As Chief Executive Vas Narasimhan focuses the Basel-based company on innovative medicines via acquisitions like this month's $8.7 billion takeover of U.S.-based AveXis, he is also plowing resources into digital technology in a bid to boost trial success, save time and cut costs.

  • Novartis' digital drive continues with eye-disease app
    Reuters29 minutes ago

    Novartis' digital drive continues with eye-disease app

    Novartis's foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies. It is using Apple's ResearchKit for its "FocalView" application to help researchers track ophthalmic disease progression by collecting data directly from patients without requiring them to travel to a doctor. As Chief Executive Vas Narasimhan focuses the Basel-based company on innovative medicines via acquisitions like this month's $8.7 billion takeover of U.S.-based AveXis, he is also plowing resources into digital technology in a bid to boost trial success, save time and cut costs.

  • The Wall Street Journal2 hours ago

    [$$] How Long Till the Final World Malaria Day?

    Wiping the disease out by 2040 could save 11 million lives.

  • Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley
    Zacks11 hours ago

    Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

    Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

  • Forbes19 hours ago

    Is Biopharma Investing Too Much In Cancer R&D?

    Jay Bradner is the president of Novartis’ Institutes for BioMedical Research, the organization entrusted with Novartis’ R&D budget of $9 billion -- one of the largest in the industry. Furthermore, Novartis is a leading innovator in the oncology field with targeted therapies as well as the recently launched CAR-T therapy Kymriah for a deadly childhood leukemia. This is a time of extraordinary promise for cancer medicine, with unambiguous evidence of progress in the innovation of both targeted and immune-oncology therapies.

  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zacks5 days ago

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

  • Novartis (NVS) Reports Encouraging Data on MS Candidate
    Zacks5 days ago

    Novartis (NVS) Reports Encouraging Data on MS Candidate

    Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks5 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
    Zacks5 days ago

    J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

    Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

  • Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint
    Investor's Business Daily5 days ago

    Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint

    Novartis beat earnings and revenue forecasts, but generics revenue tumbled and a key drug missed sales estimates.

  • Novartis AG (NVS) Q1 2018 Earnings Conference Call Transcript
    Motley Fool6 days ago

    Novartis AG (NVS) Q1 2018 Earnings Conference Call Transcript

    NVS earnings call for the period ending March 31, 2018.

  • Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
    Zacks6 days ago

    Novartis (NVS) Beats Earnings and Revenue Estimates in Q1

    Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.

  • Novartis CEO feels heat on U.S. generics, Cosentyx drop
    Reuters6 days ago

    Novartis CEO feels heat on U.S. generics, Cosentyx drop

    Swiss drugmaker Novartis' (NOVN.S) first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit. While Narasimhan confirmed 2018 growth targets, his Cosentyx drug for psoriasis and arthritis missed analyst expectations with revenue plunging from the fourth quarter.

  • Reuters - UK Focus6 days ago

    Novartis CEO feels heat on U.S. generics, Cosentyx drop

    Swiss drugmaker Novartis' first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit. While Narasimhan confirmed 2018 growth targets, his Cosentyx drug for psoriasis and arthritis missed analyst expectations with revenue plunging from the fourth quarter.

  • Associated Press6 days ago

    Novartis: 1Q Earnings Snapshot

    On a per-share basis, the Basel, Switzerland-based company said it had net income of 86 cents. Earnings, adjusted for non-recurring costs, came to $1.28 per share. The drugmaker posted revenue of $12.69 ...

  • Associated Press6 days ago

    Novartis 1Q profit jumps 12 percent as heart drug sales soar

    GENEVA (AP) — Swiss pharmaceuticals company Novartis says net income jumped 12 percent in the first quarter, pointing to explosive growth in its heart-failure drug Entresto as its rollout continues, and powerful double-digit percentage growth for psoriasis drug Cosentyx.

  • The Wall Street Journal6 days ago

    [$$] Novartis Buoyed by Heart Drug

    Swiss pharma giant Novartis said its first-quarter net profit rose to $2.03 billion, boosted by drugs Entresto and Cosentyx.

  • Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria
    Bloomberg7 days ago

    Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria

    GlaxoSmithKline Plc and Novartis AG will contribute research funds to an almost $4 billion global effort to combat malaria as drug-resistant strains of the disease threaten to undo years of progress.

  • What's in Store for Novartis (NVS) This Earnings Season?
    Zacks8 days ago

    What's in Store for Novartis (NVS) This Earnings Season?

    We expect investors to focus on the performance of newly launched drugs when Novartis (NVS) reports its first-quarter results.

  • Motley Fool8 days ago

    Did Novartis Overpay for AveXis?

    $9.8 billion isn’t pocket change, but AveXis presents some huge potential opportunities down the road.

  • Motley Fool8 days ago

    How Did Biogen Miss AveXis?

    Biogen shareholders are probably not thrilled to see Novartis’ latest acquisition. What was Biogen thinking?

  • Motley Fool8 days ago

    What Novartis Bought in AveXis

    Novartis’ $9.8 billion acquisition of AveXis signals some pretty exciting long-term focus in promising gene therapies.

  • The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
    Zacks9 days ago

    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool11 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these red-hot biotech stocks keep the momentum going?

  • Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
    Zacks11 days ago

    Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

    Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes